NanoVibronix
NAOV | NASDAQ
$1.90
+$0.02 (+1.06%)
At close: Mar 11, 2026, 09:30 AM ET
NanoVibronix Company Profile
Company profile explainedCompany Profile
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.
Key Executives
| Name | Position |
|---|---|
| Doron Robert Besser | Chief Executive Officer & Director |
| Stephen R. Brown | Chief Financial Officer |
| Harold Jacob | Chief Medical Officer |
| Lindsey Harrison | Vice President of Sales |
| Rita Silberberg | Executive Vice President of Finance, Chief Accounting Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | EFFECT | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | NT 10-Q | Filing |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 10, 2026 | S-3 | Filing |
| Jul 24, 2026 | DEF 14A | Filing |
| Jul 14, 2026 | PRE 14A | Filing |
| Jul 14, 2026 | 8-K | Current Report |
NanoVibronix
| Country | United States |
| IPO Date | May 28, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Doron Robert Besser |
Contact Details
525 Executive Boulevard Elmsford,
New York 10523 United States
Stock Details
| Ticker Symbol | NAOV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J884 |
| ISIN Number | US63008J8844 |
| SIC Code | 3842 |
Add to Watchlist
Select watchlists to add or remove NAOV